Advertisement


Sean Khozin, MD, MPH, on Delivering Precision Cancer Care in the Era of Digital Medicine

SITC 2021

Advertisement

Sean Khozin, MD, MPH, of CancerLinQ, discusses the therapeutic advances that have made cancer care more targeted, even as real-world patient outcomes lag behind those reported in clinical trials. Dr. Khozin makes the case for the use of digital decision support tools to advance precision at the point of care.



Related Videos

Immunotherapy

Patrick Hwu, MD, and Mary Dean, JD, CAE, on What’s Ahead for Cancer Immunology and SITC

Patrick Hwu, MD, of Moffitt Cancer Center and President of the Society for Immunotherapy of Cancer (SITC), and Mary Dean, JD, CAE, SITC Executive Director, discuss the organization’s mission, strides made in cancer immunology, meeting the challenge of immunoresistance, and the new SITC app for clinical practice guidelines. This app places a useful tool in the hands of health-care providers, one that can be continually updated as the science evolves.

Immunotherapy
Solid Tumors
Colorectal Cancer
Head and Neck Cancer

Mehmet Altan, MD, on Solid Tumors: Interim Safety and Efficacy Results on NKTR-255 Plus Cetuximab

Mehmet Altan, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from a phase Ib dose-escalation study, which showed early evidence of activity for NKTR-255, an investigational IL-15 receptor agonist, plus cetuximab in patients with solid tumors. Treatment appeared to lead to expansion and proliferation of NK and CD8+ cells (Abstract 957).

Immunotherapy
COVID-19

Jeffrey Weber, MD, PhD, on Coronavirus, Cancer, and Immunotherapy: Navigating Clinical Trials and Treatment

Jeffrey Weber, MD, PhD, of NYU Langone Medical Center, offers his perspective on the impact of the COVID-19 pandemic on oncology care and cancer clinical trials, as clinicians strive to provide optimal treatment to patients while reducing their risk of contracting the coronavirus. The steep decline in trial enrollment has recovered, with many of the changes in how research was conducted as a result of the pandemic still in place and improving the process going forward.

Immunotherapy
COVID-19

Hannah E. Dzimitrowicz, MD, on COVID-19 Vaccination in Patients With Cancer Receiving Immune Checkpoint Inhibitors

Hannah E. Dzimitrowicz, MD, of Duke Cancer Center, discusses study results showing that in patients with melanoma and renal cell cancer receiving immune checkpoint inhibitor therapy, the COVID-19 vaccination appears to be well tolerated and safe. A higher rate of post-vaccination symptoms reported in these patients is likely related to more frequent visits compared with controls (Abstract 625).

Immunotherapy

Yuki Muroyama, MD, PhD, on A Novel Marker of Clinical Response to PD-1 Blockade Under Study

Yuki Muroyama, MD, PhD, of the University of Pennsylvania Perelman School of Medicine, discusses the interaction between the immune system and a novel marker—T-cell DNA damage and repair response—to understand how that interaction may affect immune cell biology and therapeutic response (Abstract 310).

 

Advertisement

Advertisement



Advertisement